目的 探討丹香冠心注射液聯(lián)合替格瑞洛片治療急性心肌梗死的臨床療效。方法 選取2019年2月—2023年5月在首都醫(yī)科大學(xué)附屬北京潞河醫(yī)院接受治療的急性心肌梗死患者95例。依據(jù)用藥情況分為對照組（47例）和治療組（48例）。對照組口服替格瑞洛片，90 mg/次，2次/d。治療組在對照組的基礎(chǔ)上靜脈滴注丹香冠心注射液，20 mL加入5%葡萄糖注射液250 mL，1次/d。兩組患者治療4周。觀察兩組患者臨床療效，比較治療前后兩組患者左心室收縮末期內(nèi)徑（LVESD）、左心室射血分?jǐn)?shù)（LVEF）、心臟指數(shù)（CI）、心輸出量（CO）和E峰流速/A峰流速（E/A）、左心室后壁厚度（LVPWT）、左室心肌重量指數(shù)（LVMI）以及舒張期室間隔厚度（IVST）、髓過氧化物酶（MPO）、血清淀粉樣蛋白A1（SAA1）和可溶性生長刺激表達(dá)基因2蛋白（sST2）水平。結(jié)果 治療后，治療組總有效率為89.58%，明顯高于對照組（70.21%，P＜0.05）。治療后，兩組患者LVESD、LVPWT、IVST、MPO、SAA1和sST2指標(biāo)水平明顯降低，而LVEF、CI、CO、E/A和LVMI指標(biāo)顯著升高（P＜0.05），且治療組患者這些指標(biāo)水平明顯好于對照組（P＜0.05）。結(jié)論 丹香冠心注射液聯(lián)合替格瑞洛片可顯著提高急性心肌梗死治療的臨床有效率，改善心肌功能和逆轉(zhuǎn)心室重構(gòu)，降低心肌損傷和炎癥反應(yīng)。

Objective To investigate the clinical effect of Danxiang Guanxin Injection combined with Ticagrelor Tablets in treatment of acute myocardial infarction. Methods Patients (95 cases) with acute myocardial infarction in Beijing Luhe Hospital, Capital Medical University from February 2019 to May 2023 were divided into control (47 cases) and treatment (48 cases) group according to the different treatments. Patients in the control group were po administered with Ticagrelor Tablets, 90 mg/time, twice daily. Patients in the treatment group were iv administered with Danxiang Guanxin Injection on the basis of the control group, 20 mL added into 5% glucose injection 250 mL, once daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical evaluations were evaluated, the levels of LVESD, LVEF, CI, CO, E/A, LVPWT, IVST, LVM, MPO, SAA1 and sST2 in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 89.58%, which was significantly higher than that of the control group (70.21%, P < 0.05). After treatment, the levels of LVESD, LVPWT, IVST, MPO, SAA1, and sST2 were significantly decreased, while LVEF, CI, CO, E/A, and LVMI were significantly increased in two groups (P < 0.05), and the level of these indexes in the treatment group was significantly better than that in the control group (P < 0.05). Conclusion Danxiang Guanxin Injection combined with Ticagrelor Tablets can significantly improve the clinical effective rate of acute myocardial infarction, improve myocardial function and reverse ventricular remodeling, and reduce myocardial injury and inflammation.

R972

北京市通州區(qū)支持科技創(chuàng)新專項項目（KJ2018CX009-40）